Provectus Pharmaceuticals
Pharmaceutical ManufacturingTennessee, United States0-1 Employees
Provectus Pharmaceuticals (PVCT on the bulletin board OTC exchange) The Anti-Cancer company One of the most exciting anti- cancer compounds is emerging. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a liquid that is injected directly into certain types of tumors and has been shown to obliterate many of them with little or no toxic side effects. Further, Provectus researchers have also seen something which was initially unexpected. Injection of the compound often causes a reduction in non-targeted tumors as well as the ones that have been directly injected. This surprising systemic effect is called the “bystander effect”. It also suggests the emergence of a powerful and safe systemic anti-metastatic treatment. The primary ingredient in the compound, known as PV-10, has a long history of use as a “maker die” and is known to have few, if any, toxic side effects in humans and other mammals. The current trials have been confirming the general safety of the compound. Provectus is moving as quickly as it can, without sacrificing the integrity of the study, to complete its Phase 2 clinical trials on Melanoma, to move forward on Phase 1 trial in liver and perhaps Phase 2 in breast cancer and to open up PV-10 for “compassionate use” in both Australia and the US. A compassionate use application is one where other cancers are treated beyond any FDA protocol. They are hoping that their product can make the difference in the lives of as many people as it would be applicable for.
1-888-653-2347 
support@leadiq.com 
